Alphatec (NASDAQ:ATEC) Shares Gap Down – What’s Next?

Alphatec Holdings, Inc. (NASDAQ:ATEC)’s share price gapped down before the market opened on Monday . The stock had previously closed at $22.65, but opened at $21.47. Alphatec shares last traded at $18.4560, with a volume of 1,852,698 shares.

More Alphatec News

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Alphatec secured exclusive U.S. rights to Theradaptive’s OsteoAdapt® regenerative platform, a strategic partnership that could expand ATEC’s biologics pipeline and long‑term addressable market in spinal fusion. PR Newswire
• Positive Sentiment: Analysts at HC Wainwright and Needham reaffirmed “buy” ratings and set $24 and $22 price targets, respectively, signaling analyst confidence that shares have upside versus current levels. Benzinga TickerReport
• Positive Sentiment: Industry coverage notes joint upside with partners (e.g., Carlsmed) and expectations for material revenue growth in 2025, reinforcing the narrative of accelerating top‑line momentum for ATEC. Becker’s Spine
• Neutral Sentiment: Alphatec reported preliminary, unaudited Q4 and FY‑2025 revenue results that modestly exceeded consensus (Q4 guidance ~$212.2M–$213.2M vs. ~$209.3M consensus; FY‑2025 ~$763.4M–$764.4M vs. ~$760.6M consensus). However, EPS guidance was not clearly communicated in the release, leaving investors uncertain about profitability trajectory. BusinessWire
• Negative Sentiment: Markets reacted poorly to the company’s 2026 outlook (revenue guidance provided but EPS guidance was unclear/underwhelming in the eyes of investors), triggering a selloff and headlines that the stock “tumbled” after disappointing guidance. That reaction drove today’s share weakness despite revenue beats. Investing.com
• Negative Sentiment: Insider selling: CEO Miles Patrick recently sold ~100,000 shares (~$2.1M), which some investors interpret as a negative signal on near‑term conviction and may have added pressure to the move lower. Motley Fool

Analysts Set New Price Targets

Several research firms have commented on ATEC. HC Wainwright restated a “buy” rating and issued a $24.00 price objective on shares of Alphatec in a research report on Monday. Piper Sandler reissued an “overweight” rating and set a $25.00 price target (up from $20.00) on shares of Alphatec in a report on Friday, October 31st. Loop Capital set a $25.00 price target on shares of Alphatec in a research report on Wednesday, December 10th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Alphatec in a research report on Monday. Finally, Lake Street Capital set a $25.00 target price on Alphatec and gave the company a “buy” rating in a research report on Friday, October 31st. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and an average price target of $22.82.

Alphatec Price Performance

The stock’s 50-day moving average price is $20.74 and its 200 day moving average price is $16.42. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 43.02. The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -17.28 and a beta of 1.01.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. The business’s revenue was up 30.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. Equities research analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alphatec news, major shareholder Squadron Capital Llc sold 250,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $20.80, for a total value of $5,200,000.00. Following the completion of the sale, the insider directly owned 11,145,045 shares in the company, valued at $231,816,936. This represents a 2.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David R. Pelizzon sold 250,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $20.80, for a total value of $5,200,000.00. Following the completion of the sale, the director directly owned 11,145,045 shares of the company’s stock, valued at $231,816,936. This trade represents a 2.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,403,342 shares of company stock worth $69,816,381. 22.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alphatec

Institutional investors and hedge funds have recently bought and sold shares of the company. Emerald Advisers LLC grew its holdings in shares of Alphatec by 3.8% in the second quarter. Emerald Advisers LLC now owns 1,684,334 shares of the medical technology company’s stock valued at $18,696,000 after purchasing an additional 60,885 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Alphatec by 7,083.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 750,429 shares of the medical technology company’s stock valued at $10,911,000 after buying an additional 739,982 shares during the period. American Century Companies Inc. grew its stake in shares of Alphatec by 6.0% in the second quarter. American Century Companies Inc. now owns 6,177,161 shares of the medical technology company’s stock worth $68,567,000 after acquiring an additional 347,130 shares in the last quarter. Voya Investment Management LLC grew its stake in shares of Alphatec by 60.1% in the first quarter. Voya Investment Management LLC now owns 49,561 shares of the medical technology company’s stock worth $503,000 after acquiring an additional 18,605 shares in the last quarter. Finally, Truist Financial Corp purchased a new stake in shares of Alphatec during the second quarter worth $216,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.